The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase.
Open accessAbstract
Selective inhibition of the inducible isoform of prostaglandin G/H synthase (cyclooxygenase-2; COX2; EC 1.14.99.1) can be achieved with compounds of the general form of aryl methyl sulfonyls and aryl methyl sulfonamides. DuP 697 and NS-398 are representative examples of these compounds. Both inhibit the constitute (COX1) and inducible (COX2) isoforms of the enzyme with equal potency shortly after mixing, but their potencies increase with time for COX2 selectively. This time-dependent inhibition follows first-order kinetics, and the rate constant for inactivation of COX2 is dose dependent for both compounds. Kinetic analysis allows us to determine KI and kinact (the maximal rate of inactivation) for each inhibitor. The potency of both compounds is substrate concentration dependent, as expected for time-dependent competitive inhibitors. COX2 that has been incubated with these inhibitors, and then extensively dialyzed against buffer, shows no recovery of enzyme activity, while complete recovery of activity is seen for COX1. Thus, these inhibitors irreversibly inactivate COX2 with time, while showing minimal reversible inhibition of COX1. We isolated these inhibitors after long incubation with excess enzyme and subsequent denaturation of the enzyme. Both inhibitors showed no loss of potency resulting from interactions with COX2, suggesting that inhibition is not mediated by covalent modification of the enzyme. These data suggest that binding of these inhibitors to COX2 induces a slow structural transition of the enzyme that results in its selective inactivation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J., & Vane, J. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11693 · Cited by 1,659
Esters of Methanesulfonic Acid as Irreversible Inhibitors of Acetylcholinesterase
Kitz, R., & Wilson, I. B. (1962) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50153-8 · Cited by 1,519
Hla, T., & Neilson, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7384 · Cited by 1,465
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C., & Seibert, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3228 · Cited by 1,310
Acetylation of prostaglandin synthase by aspirin.
Roth, G. J., Stanford, N., & Majerus, P. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.3073 · Cited by 1,009
Futaki, N., Takahashi, S., Yokoyama, M., Arai, I., Higuchi, S., & Otomo, S. (1994) · Prostaglandins · doi:10.1016/0090-6980(94)90074-4 · Cited by 826
cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.
O'Banion, M. K., Winn, V. D., & Young, D. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.4888 · Cited by 821
DeWitt, D. L., & Smith, W. L. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.5.1412 · Cited by 596
Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells.
Maier, J. A., Hla, T., & Maciag, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38515-1 · Cited by 482
Cited by
Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2
Smith, W. L., Garavito, R. M., & DeWitt, D. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33157 · Cited by 1,978
Penning, T. D., Talley, J. J., Bertenshaw, S. R., Carter, J. S., Collins, P. W., Docter, S., Graneto, M. J., Lee, L. F., Malecha, J. W., Miyashiro, J. M., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960803q · Cited by 1,965
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., Gildehaus, D., iyashiro, J. M., Penning, T. D., Seibert, K., et al. (1996) · Nature · doi:10.1038/384644a0 · Cited by 1,917
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons, D. L., Botting, R. M., & Hla, T. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.3 · Cited by 1,693
Multiple Female Reproductive Failures in Cyclooxygenase 2–Deficient Mice
Lim, H., Paria, B. C., Das, S. K., Dinchuk, J. E., Langenbach, R., Trzaskos, J. M., & Dey, S. K. (1997) · Cell · doi:10.1016/s0092-8674(00)80402-x · Cited by 1,430
Self-citationThe role of cyclooxygenases in inflammation, cancer, and development
Williams, C. S., Mann, M., & DuBois, R. N. (1999) · Oncogene · doi:10.1038/sj.onc.1203286 · Cited by 1,417
Molecular Cues to Implantation
Dey, S. K., Lim, H., Das, S. K., Reese, J., Paria, B. C., Daikoku, T., & Wang, H. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0020 · Cited by 1,105
Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part I)
Taketo, M. M. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.20.1529 · Cited by 757
The drug–target residence time model: a 10-year retrospective
Copeland, R. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.18 · Cited by 722
Self-citationProstaglandin Endoperoxide H Synthases-1 and -2
Smith, W. L., & Dewitt, D. L. (1996) · Advances in Immunology · doi:10.1016/s0065-2776(08)60430-7 · Cited by 711
Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
Luong, C., Miller, A., Barnett, J., Chow, J., Ramesha, C., & Browner, M. F. (1996) · Nature Structural Biology · doi:10.1038/nsb1196-927 · Cited by 618
Wang, H., Nair, M. G., Strasburg, G. M., Chang, Y.-C., Booren, A. M., Gray, J. I., & DeWitt, D. L. (1999) · Journal of Natural Products · doi:10.1021/np990184z · Cited by 615
Redesigning an FKBP–ligand interface to generate chemical dimerizers with novel specificity
Clackson, T., Yang, W., Rozamus, L. W., Hatada, M., Amara, J. F., Rollins, C. T., Stevenson, L. F., Magari, S. R., Wood, S. A., Courage, N. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10437 · Cited by 558
Bioactive Benzofuran derivatives: A review
Khanam, H., & Shamsuzzaman (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.039 · Cited by 554
Structural and Functional Basis of Cyclooxygenase Inhibition
Blobaum, A. L., & Marnett, L. J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0613166 · Cited by 550
Arachidonic Acid Oxygenation by COX-1 and COX-2
Marnett, L. J., Rowlinson, S. W., Goodwin, D. C., Kalgutkar, A. S., & Lanzo, C. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.22903 · Cited by 523
Enzymes of the Cyclooxygenase Pathways of Prostanoid Biosynthesis
Smith, W. L., Urade, Y., & Jakobsson, P.-J. (2011) · Chemical Reviews · doi:10.1021/cr2002992 · Cited by 503
Mechanism of Action of Anti-Inflammatory Drugs
Vane, J. R., & Botting, R. M. (1996) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749609097226 · Cited by 465
Riendeau, D., Percival, M. D., Brideau, C., Charleson, S., Dubé, D., Ethier, D., Falgueyret, J.-P., Friesen, R. W., Gordon, R., Greig, G., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38776-2 · Cited by 460
The development of COX2 inhibitors
Flower, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1034 · Cited by 459
Gierse, J. K., McDonald, J. J., Hauser, S. D., Rangwala, S. H., Koboldt, C. M., & Seibert, K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.26.15810 · Cited by 410
Chan, C.-C., Boyce, S., Brideau, C., Charleson, S., Cromlish, W., Ethier, D., Evans, J., Ford-Hutchinson, A. W., Forrest, M. J., Gauthier, J. Y., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34934-1 · Cited by 398
Biochemical mechanisms of drug action: what does it take for success?
Swinney, D. C. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1500 · Cited by 394
Fever and hypothermia in systemic inflammation: recent discoveries and revisions
Romanovsky, A. (2005) · Frontiers in Bioscience · doi:10.2741/1690 · Cited by 344
COX-2 Inhibitors and Cardiovascular Risk
Funk, C. D., & FitzGerald, G. A. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318157f72d · Cited by 330
EHRICH, E., DALLOB, A., DELEPELEIRE, I., VANHECKEN, A., RIENDEAU, D., YUAN, W., PORRAS, A., WITTREICH, J., SEIBOLD, J., & DESCHEPPER, P. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70113-x · Cited by 322
Riendeau, D., Percival, M. D., Boyce, S., Brideau, C., Charleson, S., Cromlish, W., Ethier, D., Evans, J., Falgueyret, J. ‐., Ford‐Hutchinson, A. W., et al. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701076 · Cited by 322
COX-2: A Target for Colon Cancer Prevention
Marnett, L. J., & DuBois, R. N. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082301.164620 · Cited by 313
Selective inhibition of cyclooxygenase-2 by C-phycocyanin, a biliprotein from Spirulina platensis
Reddy, C. M., Bhat, V. B., Kiranmai, G., Reddy, M. N., Reddanna, P., & Madyastha, K. M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3725 · Cited by 310
Shafi, S., Mahboob Alam, M., Mulakayala, N., Mulakayala, C., Vanaja, G., Kalle, A. M., Pallu, R., & Alam, M. S. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.032 · Cited by 301
Fatty Acid Substrate Specificities of Human Prostaglandin-endoperoxide H Synthase-1 and −2
Laneuville, O., Breuer, D. K., Xu, N., Huang, Z. H., Gage, D. A., Watson, J. T., Lagarde, M., DeWitt, D. L., & Smith, W. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.33.19330 · Cited by 301
Kinetic basis for selective inhibition of cyclo-oxygenases
Gierse, J. K., Koboldt, C. M., Walker, M. C., Seibert, K., & Isakson, P. C. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3390607 · Cited by 287
Effects of Celecoxib and Naproxen on Renal Function in the Elderly
Whelton, A., Schulman, G., Wallemark, C., Drower, E. J., Isakson, P. C., Verburg, K. M., & Geis, G. S. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.10.1465 · Cited by 280
Cox-2-Selective Inhibitors: The New Super Aspirins
DeWitt, D. L. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23023-6 · Cited by 261
The Design of Covalent Allosteric Drugs
Nussinov, R., & Tsai, C.-J. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124401 · Cited by 112
Mangiferin from Pueraria tuberosa reduces inflammation via inactivation of NLRP3 inflammasome
Bulugonda, R. K., kumar, K. A., Gangappa, D., Beeda, H., Philip, G. H., Muralidhara Rao, D., & Faisal, S. M. (2017) · Scientific Reports · doi:10.1038/srep42683 · Cited by 74
“Enzymatic activities of both COX-1 and COX-2 were measured according to the method of Copeland et al. with slight modifications, using a chomogenic assay based on the oxidation of N,N,N ′ ,N ′ -tetramethyl-p-phenylenediamine (TMPD) during the reduction of PGG2 to PGH2 50–52 .”
Metadata
- Authors
- Copeland, R. A., Williams, J. M., Giannaras, J., Nurnberg, S., Covington, M., Pinto, D., Pick, S., & Trzaskos, J. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1994-11-08
- Volume
- 91
- Issue
- 23
- Pages
- 11202-11206
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2039358393
- Cited by
- 408
- References
- 17
- FWCI
- 22.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.